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BACKGROUND: In the United States, Black men have a higher risk of prostate cancer and worse survival than do White men, but it is
unclear whether this is because of differences in diagnosis and management. We re-examined these differences in the United
Kingdom, where health care is free and unlikely to vary by socioeconomic status.
METHODS: This study is a population-based retrospective cohort study of men diagnosed with prostate cancer with data on ethnicity,
prognostic factors, and clinical care. A Delphi panel considered the appropriateness of investigations and treatments received.
RESULTS: At diagnosis, Black men had similar clinical stage and Gleason scores but higher age-adjusted prostate-specific antigen levels
(geometric mean ratio 1.41, 95% confidence interval (95% CI): 1.15–1.73). Black men underwent more investigations and were more
likely to undergo radical treatment, although this was largely explained by their younger age. Even after age adjustment, Black men
were more likely to undergo a bone scan (odds ratio 1.37, 95% CI: 1.05–1.80). The Delphi analysis did not suggest differential
management by ethnicity.
CONCLUSIONS: This UK-based study comparing Black men with White men found no evidence of differences in disease characteristics
at the time of prostate cancer diagnosis, nor of under-investigation or under-treatment in Black men.
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A recent systematic review comparing Black men with White men
diagnosed with prostate cancer found evidence of poorer
prognosis in Black men (Evans et al, 2008). All studies included
in the meta-analysis were based in the United States where, on
average, Black men occupy less privileged socioeconomic positions
(Shapiro and Oliver, 1996; Jones et al, 2008) and where access to
health services is largely determined by the patient’s ability to pay.
Hence, the poorer prognosis in Black men is not necessarily due to
a more aggressive disease type. Alternative possibilities are that
Black men in the United States are diagnosed later because of
poorer access to diagnostic services (Institute of Medicine, 2001),
may have a poverty-related higher risk of comorbidity and hence
less resilience to disease progression (Davey Smith et al, 1998),
and may have their disease managed less aggressively (Shavers
and Brown, 2002; Shavers et al, 2004a,b). Meta-analysis of findings
from studies accounting for clinical characteristics at diagnosis
and, in some cases, socioeconomic status suggested a reduced but
still apparent disadvantage for Black men with prostate cancer in
terms of prostate-cancer-specific mortality and biochemical
recurrence (Evans et al, 2008). In fact, few studies measured
socioeconomic status, and all relied on ecological measures as a
proxy indicator of individual status.
The possibility remains that a better control of confounding
factors may completely account for the observed poorer prognosis
in US-resident Black men with prostate cancer. Alternatively, the
examination of cohorts with minimal ethnic variation in socio-
economic factors and clinical management could result in greater
confidence that any differences in prognosis are more likely due to
biological factors. The Prostate Conditions in Ethnic Subgroups
(PROCESS) cohort is based in Southern England, where free
medical care is available to all from the UK National Health
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sService. Studies of this cohort have shown a higher rate of incident
prostate cancer in Black men compared with White men
(Ben-Shlomo et al, 2008), and although Black men were more
likely to work in manual occupations (81 vs 67%) and to live in
less-affluent areas, there were no marked differences in knowledge
of prostate cancer, in delays before seeking medical attention, in
the average prostate-specific antigen (PSA) level at diagnosis, or in
levels of comorbidity (Metcalfe et al, 2008).
In this analysis, we compare diagnostic investigations, the
clinical stage of disease at presentation, and initial management
between Black men and White men diagnosed with prostate
cancer. Variations in management may be difficult to interpret, as
one group may be either managed too aggressively or the other
group may be under-managed. Therefore, we used a ‘Delphi’
consensus approach to allow us to classify whether management
was appropriate for a large number of clinical scenarios (Shekelle
et al, 1998) and then compared this with our observed patterns of
care by ethnicity. This approach allows one to conclude whether
any observed variations in management between Black men and
White men are accounted for by differences in clinical need
between the two groups of men.
PARTICIPANTS AND METHODS
The Prostate Conditions in Ethnic Subgroups, a population-based
retrospective cohort study, has been previously described
(Ben-Shlomo et al, 2008; Metcalfe et al, 2008). Cases of prostate
adenocarcinoma were identified from among males residing in
four study areas (namely North Bristol, South-West London,
South-East London, and North-East London) during 1995–1999
(Bristol) or during 1997–2001 (London). Possible cases of prostate
cancer were identified from the following sequence of sources: (1)
pathology databases and (North-West London only) a urology
department database, (2) hospital discharge diagnosis files, (3)
PSA records 410ngml
 1, and (4) Cancer Registry (Bristol only).
In cases in which histological proof of cancer was not available
(e.g., having relied on PSA records), a panel of at least four
urologists classified a case vignette as a ‘clinical’ (non-histological
proven) case of prostate cancer, or excluded it because of lack of
evidence.
The South-West Multi-Centre Research Ethics Committee
approved the PROCESS study.
Men known to be alive at the time of the study were asked to
complete a questionnaire including the 2001 census questions on
ethnicity, with the next-of-kin being contacted if the man had died
more than 6 months ago. Questionnaire information determined
ethnicity for 37% of Black men and 45% of White men. If a man’s
ethnicity remained undetermined, we referred in turn to hospital
records (62% of Black men, 50% of White men) and place of
birth recorded on the death certificate (1% of Black men, 5%
White men).
Trained research nurses reviewed hospital records using a
standard proforma, extracting information on PSA measurements,
histological investigations, investigations aimed at determining
cancer stage, and initial management strategies. The North-East
London centre was restricted by time and reviewed all case notes
for Black men, and a random sample of 50% of case notes for
White men. Taking this into account, three centres completed
reviews for more than 85% of cases, whereas the North-East
London centre completed reviews for 76%.
An ecological measure of socioeconomic position was obtained
by linking each man’s home postcode to the corresponding 1998
electoral ward (http://www.edina.ac.uk/), then to the Index of
Multiple Deprivation (IMD) score for the year 2000 (http://
www.neighbourhood.statistics.gov.uk/). Six domains (namely
income; employment; health deprivation and disability; education,
skills, and training; housing; and geographical access to services)
determine the index score for an area, with higher scores
indicating greater deprivation. Occupation, available for 1249 of
the 1461 (85%) men whose medical records were reviewed, formed
the basis of an individual measure of socioeconomic position, with
occupation being classified as manual or non-manual according to
the Registrar General’s scheme (see http://www.statistics.gov.uk/).
Measures of PSA level and tumour differentiation from the time
of diagnosis and before commencing any treatment were
identified. The following categories of tumour differentiation were
distinguished: (1) Gleason scores (Gilliland et al, 2001) up to 6,
well differentiated, or moderately differentiated; (2) a Gleason
score of 7; and (3) a Gleason score of 8 or more, or poorly
differentiated. The use of MRI or CT scans to identify metastases
was noted, with stage at diagnosis being recorded according to the
TNM system (Ohori et al, 1994). We distinguished three categories:
(1) tumour confined to the prostate, T1/T2; (2) tumour spread to
structures adjacent to the prostate, T3/T4/N1; and (3) tumour
spread to distant structures, M1. Finally, for this study, the initial
management strategy was determined with the following four
categories distinguished: (1) radical prostatectomy with curative
intent; (2) radiotherapy with curative intent; (3) hormone therapy,
including orchidectomy, with the intention of slowing progression;
and (4) conservative treatment, including watchful waiting,
palliative treatment, and no treatment.
A Delphi sub-study investigated the appropriate use of
diagnostic investigations and management strategies. Four uro-
logists and one oncologist working in the PROCESS study centres
were asked to independently consider 126 hypothetical patients,
constructed as combinations of age (o65, 65–74, and 75þ years),
PSA (o20, 20–99, 100þ ngml
 1), disease stage (localised, locally
advanced, and metastatic disease), Gleason score (o5, 5–7, and
8þ), and comorbidity (low and moderate/high). Each hypothe-
tical patient was rated as being appropriate for a bone scan, a CT
scan, radical prostatectomy, radical radiotherapy, hormones only,
and watchful waiting on a 1–9 scale, with 1–3 being inappropriate,
4–6 being equivocal, and 7–9 being appropriate. For each
hypothetical patient, a median of the five ratings was taken for
the appropriateness of each procedure. Each PROCESS cohort
member was then matched to a hypothetical patient according to
the above-mentioned categories of age, PSA, stage, grade, and
comorbidity, and was thus matched to median appropriateness
ratings for different investigations and approaches. In situations in
which a match with a hypothetical patient was not available, the
PROCESS cohort member was not included in this part of the
analysis.
Statistical analysis
Owing to their positively skewed distribution, PSA levels are
presented as medians with 90% ranges, and the association with
ethnicity is presented as a ratio of geometric means. Geometric
means are similar in value to medians, and their ratio can be
estimated using standard regression methods applied to natural
log-transformed PSA measurements.
Multivariable regression models estimated the associations
between race and binary factors (logistic regression), and ordered
categorical factors (ordered logistic regression) (Kirkwood and
Sterne, 2003). Odds ratios were centre and age adjusted by
including each of these covariates in regression models as four
dummy variables, distinguishing the five study centres and five age
categories. A further adjustment for socioeconomic factors was
attempted by adding three dummy variables to multivariable
models, distinguishing quartiles of IMD scores, and a single
dummy variable distinguishing men in manual occupations from
those in non-manual occupations.
Further analyses compared the use of each diagnostic investiga-
tion and treatment strategy between Black men and White men,
each analysis being stratified by how appropriate the procedure
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swas judged to be for a man by the Delphi panel. For each
procedure, an interaction test addressed the null hypothesis of
equal ethnic differences across categories of appropriateness. The
interaction test was implemented by adding extra covariates to the
regression model, which would capture any variation in the ethnic
difference across categories of appropriateness, and then testing
the null hypothesis that the coefficients for those extra terms were
all zero on the log scale. For these analyses, crude- and age-
adjusted analyses are presented, the reduced sample size not being
sufficient for centre adjustment within strata. For the same reason,
age is included as a linear continuous covariate in these analyses.
Agreement between Delphi panel members with regard to the
use of three broad categories (inappropriate, equivocal, and
appropriate) for each investigation and procedure was estimated
using an unweighted, multi-rater k-statistic applied to data from
all 126 hypothetical patients (Landis and Koch, 1977).
CI denotes confidence interval, and all P-values are two-tailed.
Analyses were undertaken using Stata version 10 (StataCorp,
College Station, TX, USA, 2007).
RESULTS
As previously reported, Black men presented at a younger age
(mean 67.9 years, s.d. 7.3 years, n¼547) compared with White
men (mean 73.3 years, s.d. 8.8 years, n¼1319), with the observed
distributions being consistent with normal distributions in the
population in each case (Metcalfe et al, 2008). Review of hospital
records was completed and provided data for 473 (86%) Black men
and 988 (91% of the 1098 reviews planned) White men. Where
available, the median pre-treatment PSA level was 25ngml
 1 for
Black men (90% range 4.8–822ngml
 1; n¼436) and 23ngml
 1
for White men (90% range 3.8–1325ngml
 1; n¼863). The centre-
adjusted analysis of PSA levels provided no convincing evidence of
a difference (geometric mean ratio 1.11, 95% CI: 0.91–1.35,
P¼0.32), but there was strong evidence of higher levels in Black
men than in White men of similar age (geometric mean ratio 1.41,
95% CI: 1.15–1.73, P¼0.001). Only 16% of Black men and 11% of
White men were diagnosed in the absence of symptoms, after a
PSA test.
A histological report was available from the time of diagnosis for
more than 90% of men, with the distribution of reported Gleason
scores being comparable between Black men and White men
(Table 1). There was some evidence that Black men were more
likely to undergo a bone scan or a CT scan, but for the latter, the
age-adjusted analysis suggested that this was because of Black men
being diagnosed at a younger age (Table 1). The distribution of
cancer stages at diagnosis was very similar between Black men and
White men, with three-quarters of both groups being diagnosed
while their disease was still localised (Table 1). An additional
adjustment of these analyses for the occupation- and area of
residence-based measures of socioeconomic position did not affect
the estimated differences between Black men and White men (data
not shown).
Of those men whose disease stage was recorded, the initial
treatment plan was determined by reviewing the medical records
of 415 out of 437 (95%) Black men, and 851 out of 891 (96%) White
men. The majority of men diagnosed with cancer spread to
adjacent structures (T3/T4/N1) were initially treated with hor-
mones (20 out of 28 (71%) Black men and 34 out of 54 (63%)
White men) or radiotherapy (8 out of 28 (29%) Black men and 10
out of 54 (19%) White men). Men diagnosed with metastatic
cancer were predominantly treated with hormones (68 out of 73
(93%) Black men and 152 out of 164 (93%) White men), with a
handful receiving palliative treatment (4 out of 73 (5%) Black men
and 9 out of 164 (5%) White men). All four noted management
Table 1 Investigations and disease characteristics at diagnosis
Black men White men Centre adjusted Centre and age adjusted
n (%) n (%) OR (95% CI) P-value OR (95% CI) P-value
Has hospital records review
(n¼1461)
473 988
Histological diagnosis (n¼1437)
No 15 (3) 58 (6)
Yes 451 (97) 913 (94) 1.27 (0.68, 2.36) 0.45 0.81 (0.41, 1.58) 0.53
Gleason score at diagnosis (n¼1309)
p6 242 (55) 486 (56)
7 105 (24) 190 (22)
8/10 91 (21) 195 (22)
Trend per category increase 0.95 (0.75, 1.19) 0.66 1.08 (0.85, 1.37) 0.54
Bone scan (n¼1461)
Not recorded
a 45 (10) 91 ( 9)
No
a 77 (16) 268 (27)
Yes 351 (74) 629 (64) 1.50 (1.16, 1.95) 0.002 1.37 (1.05, 1.80) 0.02
CT investigation (n¼1461)
Not recorded
a 118 (25) 209 (21)
No
a 268 (57) 639 (65)
Yes 87 (18) 140 (14) 1.33 (0.97, 1.83) 0.079 1.03 (0.74, 1.45) 0.85
Stage at diagnosis (n¼1328)
T1/T2 332 (76) 663 (74)
T3/T4/N1 30 (7) 56 (6)
M1 75 (17) 172 (19)
Trend per category increase 1.02 (0.77, 1.35) 0.91 1.13 (0.84, 1.51) 0.43
Abbreviations: CI, confidence interval; CT¼computed tomography; OR¼odds ratio.
aThese two groups combined and used as the comparison in calculating the OR.
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sstrategies were used in the case of men diagnosed with localised
cancer (Table 2). There was evidence that Black men were more
likely than White men to undergo a curative treatment strategy for
their localised cancer, but the age-adjusted analyses indicated that
this was because of the younger age of Black men at diagnosis
(Table 2). In fact, although the evidence was very weak and
consistent with chance, Black men seemed to be less likely to
undergo curative treatment when compared with their same-age
White counterparts. Additional adjustment for occupation- and
area of residence-based measures of socioeconomic position
reduced the observed difference between Black men and White
men in curative treatment (odds ratio 0.81, 95% CI: 0.54–1.24),
although this analysis was only possible for men with a known
occupation (720 out of 937 (77%)).
Supplementary Appendix 1 presents the hypothetical patients
from the Delphi exercise who most commonly matched to
PROCESS cohort members, with the appropriateness ratings for
investigations and management strategies. There was fair-to-
moderate agreement, measured using the k-statistic, between
Delphi panel members on the appropriateness of interventions for
the set of hypothetical patients (prostatectomy 0.31, radiotherapy
0.44, watchful waiting 0.18). Agreement among panel members
with regard to investigations was at chance levels, although for
bone scanning, this was because of all five panel members
considering a bone scan to be appropriate for the large majority of
patients, with this lack of variation not allowing inter-rater
agreement to be apparent.
In Table 3, those cohort members matched to a hypothetical
patient are stratified by their suitability for each investigation and
management strategy. The odds of undergoing each procedure are
then compared between Black men and White men within each
stratum of suitability. There is no convincing evidence that the
differences between Black men and White men observed in Table 2
varied by the judged appropriateness of the procedures (all
interaction P-values are 40.3). With regard to crude comparisons,
there was a trend for the higher rate of radiotherapy in Black men
to be particularly apparent among men for whom the treatment
was judged appropriate. With regard to age-adjusted analyses, the
reduced rates of radiotherapy and surgery in Black men when
compared with same-age White men (Table 2) seemed to occur in
clinical scenarios in which the decision to undertake these
procedures was equivocal.
The Delphi committee recommended bone scanning for all men.
This is inconsistent with recent UK National Institute for Health
and Clinical Excellence (NICE) guidelines, which recommend
against routine bone scanning for men with ‘low risk’
(PSA o0ngml
 1 and Gleason score of p6) localised prostate
cancer (National Institute for Health Clinical Excellence, 2008).
Owing to this reason, as well as to assist the interpretation of our
findings, we stratified the comparison of bone scan and CT scan
rates in men with clinically localised disease by the NICE risk
categories. Low risk is as defined above, intermediate risk is a PSA
level between 10 and 19.99 or a Gleason score of 7, and high risk is
a PSA level 420 or a Gleason score of X8. When compared with
White men of the same age, Black men were more likely to
undergo a bone scan in all three risk categories (Table 4), and a CT
scan in the intermediate- and high-risk categories, but the wide CIs
indicate that these differences could have occurred by chance.
There was no evidence that the association between ethnicity and
undergoing either investigation varied by the NICE risk category
(P-value for interaction, 0.42 and 0.27 for bone scanning and CT
scanning, respectively).
DISCUSSION
The UK-based PROCESS cohort provides no evidence of Black
men being diagnosed with more advanced prostate cancer than
White men, although they had greater age-adjusted PSA levels.
Black men were more likely to undergo CT and MRI scans, and
were more likely to undergo curative treatment for localised
disease, but this was entirely accounted for by their younger age at
diagnosis. There is no evidence that Black men were managed less
appropriately than their same-age White counterparts, but in this
Delphi sub-study, the CIs around estimates are relatively wide.
There was evidence that White men were less likely to undergo a
bone scan, although this may be because of the older average age
of White men, allowing residual confounding by comorbidity.
Surveillance, Epidemiology, and End Results (SEER) data on
tumour grade at diagnosis are available from the California Cancer
Registry for the period between 1995 and 2004, in which they
found 24.3% of Black men and 22.9% of White men to have poorly
differentiated or undifferentiated tumours (Robbins et al, 2007).
Hence, around the turn of the century, similar proportions of
Black men and White men were diagnosed with aggressive
tumours in the United States, and in fact, these figures are very
similar to the proportions of men we found in the United Kingdom
with equivalent Gleason scores of between 8 and 10 at diagnosis
(Table 1). Compared with our data (Table 1), a greater proportion
of Californian men were diagnosed with localised (T1/T2) cancer,
with 79.2% of Black men and 84.3% of White men diagnosed while
their tumour was localised (Robbins et al, 2007). A smaller
Table 2 Initial treatment of men diagnosed with T1/T2 cancer
Adjusted for
Black men White men Centre (n¼947)
Centre and age
(n¼947)
Centre, age, grade, stage,
and comorbidity (n¼846)
n (%) n (%) OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Has T1/T2 cancer 332 663
and initial treatment recorded 314 (95) 633 (95)
No treatment 50 (16) 188 (30)
Hormone therapy 118 (38) 249 (39)
Curative radiotherapy 104 (33) 123 (19) 1.67 (1.20, 2.32) 0.002 0.85 (0.58, 1.23) 0.39 0.77 (0.51, 1.14) 0.19
Curative surgery 42 (13) 73 (12) 1.44 (0.92, 2.27) 0.114 0.67 (0.38, 1.16) 0.15 0.79 (0.42, 1.48) 0.45
Curative radiotherapy or surgery 146 (46) 196 (31) 1.57 (1.17, 2.10) 0.003 0.74 (0.52, 1.05) 0.088 0.71 (0.49, 1.03) 0.074
Abbreviations: CI, confidence interval; OR¼odds ratio. Comparisons are against the combination of no treatment+hormone therapy. Dummy covariates distinguish the five
centres, three age groups (44–68, 69–76, and 77–94 years), three groups of Gleason scores (p6, 7, and 8+), two stages (T1 and T2), and three groups of Charlson scores
(0, 1, and 2+).
Ethnicity and the management of prostate cancer in UK
S Evans et al
252
British Journal of Cancer (2010) 102(2), 249–254 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sproportion of Californian men were diagnosed with metastasised
disease (6.4% of Black men and 4.0% of White men) (Robbins
et al, 2007). These differences are potentially because of the greater
use of PSA testing in the United States during this period.
In contrast to diagnostic procedures, more differences were
apparent in initial treatment. About a third of Californian men
underwent surgery, with slightly more White men (35.7%) than
Black men (32.6%) being managed initially in this manner
Table 4 Black men and White men undergoing diagnostic procedures, by the NICE guidance risk categories for men with clinically localised disease, and
clinically advanced disease (T3/T4)
Underwent investigation; Black/White men
Underwent procedure N (%) Crude estimates Age adjusted
NICE risk category
a Black men White men OR (95% CI) OR (95% CI)
Bone scanning (n¼1068)
Low risk 39/64 (61) 73/133 (55) 1.28 (0.70, 2.35) 1.10 (0.59, 2.07)
Intermediate risk 58/72 (81) 99/147 (67) 2.01 (1.02, 3.59) 1.85 (0.92, 3.73)
High risk 171/183 (93) 277/337 (82) 3.09 (1.61, 5.90) 1.84 (0.91, 3.69)
Clinically advanced 34/39 (87) 71/93 (76) 2.11 (0.73, 6.04) 1.50 (0.50, 4.53)
Interaction P-value 0.29 0.42
CT scanning (n¼796)
Low risk 9/56 (16) 25/121 (21) 0.74 (0.32, 1.70) 0.58 (0.24, 1.39)
Intermediate risk 20/66 (30) 22/123 (18) 2.00 (1.00, 4.01) 1.94 (0.94, 4.02)
High risk 43/144 (30) 57/286 (20) 1.71 (1.08, 2.71) 1.24 (0.76, 2.02)
Clinically advanced 7/35 (20) 17/88 (19) 1.04 (0.39, 2.79) 0.98 (0.36, 2.69)
Interaction P-value 0.24 0.27
Abbreviations: CI¼confidence interval; CT¼computed tomography; NICE¼National Institute for Health and Clinical Excellence; OR¼odds ratio.
aLow risk: PSA o10ngml
 1
and Gleason score of p6; intermediate risk: PSA between 10 and 19.99 or Gleason score of 7; high risk: PSA 420 or Gleason score of X8.
Table 3 Black men and White men undergoing different procedures, by Delphi judgement on the appropriateness of those procedures
Underwent procedure;
Black men/White men
Underwent procedure N (%) Crude estimates Age adjusted
Delphi opinion on appropriateness
of procedure for patient: Black men White men OR (95% CI) OR (95% CI)
CT scan (n¼803)
Inappropriate 27/108 (25) 46/234 (20) 1.36 (0.79, 2.34) 1.05 (0.60, 1.87)
Equivocal 23/105 (22) 39/229 (17) 1.37 (0.77, 2.43) 1.10 (0.60, 2.02)
Appropriate 14/55 (25) 12/72 (17) 1.71 (0.72, 4.06) 1.64 (0.69, 3.94)
Interaction P-value 0.90 0.73
Surgical treatment (n¼711)
a
Inappropriate 0/112 (0) 6/323 (2)
Equivocal 7/48 (15) 11/ 84 (13) 1.13 (0.41, 3.15) 0.43 (0.12, 1.57)
Appropriate 31/58 (53) 40/86 (47) 1.32 (0.68, 2.57) 1.36 (0.62, 2.97)
Interaction P-value 0.81 0.15
Radiological treatment (n¼828)
b
Inappropriate 1/48 (2) 2/100 (2) 1.04 (0.09, 11.79) 0.58 (0.05, 7.12)
Equivocal 14/54 (26) 24/134 (18) 1.60 (0.76, 3.40) 0.74 (0.31, 1.78)
Appropriate 82/175 (47) 89/317 (28) 2.26 (1.54, 3.32) 1.27 (0.83, 1.96)
Interaction P-value 0.62 0.63
Hormone treatment (n¼923)
Inappropriate 5/58 (9) 4/ 74 (5) 1.65 (0.42, 6.45) 1.86 (0.46, 7.59)
Equivocal 35/127 (28) 77/260 (30) 0.90 (0.56, 1.45) 1.17 (0.71, 1.94)
Appropriate 96/130 (74) 196/274 (72) 1.12 (0.70, 1.80) 1.44 (0.86, 2.40)
Interaction P-value 0.64 0.56
No active treatment (n¼923)
Inappropriate 6/142 (4) 42/289 (15) 0.26 (0.11, 0.63) 0.40 (0.16, 1.01)
Equivocal 23/117 (20) 76/209 (36) 0.43 (0.25, 0.73) 0.65 (0.36, 1.16)
Appropriate 15/56 (27) 41/110 (37) 0.62 (0.30, 1.25) 0.84 (0.39, 1.79)
Interaction P-value 0.32 0.62
Abbreviations: CI, confidence interval; CT¼computed tomography; OR¼odds ratio.
aMen undergoing radiotherapy are excluded from the denominators.
bMen undergoing
surgery are excluded from the denominators.
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s(Robbins et al, 2007). Similarly, radiotherapy was the initial
treatment for 32.7% of White men and 30.0% of Black men
(Robbins et al, 2007). The greater use of these potentially curative
treatments in the United States is, in part, because of the younger
average age at diagnosis (median age at diagnosis in US White men
is 69 years and that in US Black men is 66 years (Karami et al,
2007)), and perhaps, in part, because of a more rapid uptake
of prostatectomy and radiotherapy in the United States during
the period studied, when they were relatively new interventions
(Collin et al, 2008). In the United Kingdom, although a curative
treatment plan was less common (Table 2), the decision to follow
such a plan was taken more equitably between Black men and
White men, with no strong evidence of a difference once the age
difference was taken into account. In fact, there is weak evidence in
our data of Black men being more likely than White men to
undergo those investigations and curative treatments if considered
to be clinically appropriate.
The PROCESS study has collected detailed demographic and
clinical information from medical records and questionnaires on a
cohort of men diagnosed with prostate cancer. A Delphi sub-study
has provided information on the medical decision-making process
of clinicians working at hospitals in which the cohort men were
diagnosed and treated. The resulting data are considerably richer
than those available to cancer registries, in spite of the PROCESS
cohort being smaller; therefore, the estimates from our stratified
analyses will be less precise. Measurement error may be a concern
for data extracted from routine medical records, although ethnic
variation in record keeping practice is unlikely. Finally, PROCESS
is a retrospective cohort study; hence, the men were diagnosed and
treated some time before the Delphi panel considered it to be
appropriate practice. However, although the Delphi panel
recommendations may vary over time, the variation will not be
associated with race, as the vignettes do not contain that
information.
To conclude, in this UK-based cohort, Black men and White
men are diagnosed with prostate cancer at comparable points in
the natural history of the disease, as determined by tumour grade
and tumour stage, although with higher age-adjusted PSA levels.
Once younger age at diagnosis is taken into account, Black men are
as likely to undergo CT or MRI scanning as White men, and are as
likely to have localised disease treated with curative intent. White
men were noted to be less likely to receive a bone scan. This
comparability between the experiences of Black men and White
men, coupled with detailed information on socioeconomic
position available for the PROCESS cohort, will assist interpreta-
tion when comparing survival between Black men and White men
after a diagnosis of prostate cancer.
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